Equitable Trust’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $7.64M | Sell |
35,133
-1,202
| -3% | -$267K | 0.35% | 59 |
|
|
2025
Q4 | $8.3M | Buy |
36,335
+363
| +1% | +$82.7K | 0.37% | 55 |
|
|
2025
Q3 | $8.33M | Buy |
35,972
+33
| +0.1% | +$6.72K | 0.38% | 54 |
|
|
2025
Q2 | $6.67M | Buy |
35,939
+193
| +0.5% | +$35.9K | 0.33% | 56 |
|
|
2025
Q1 | $7.49M | Buy |
35,746
+923
| +3% | +$179K | 0.41% | 47 |
|
|
2024
Q4 | $6.19M | Buy |
34,823
+597
| +2% | +$110K | 0.35% | 52 |
|
|
2024
Q3 | $6.76M | Buy |
34,226
+2,698
| +9% | +$504K | 0.43% | 44 |
|
|
2024
Q2 | $5.41M | Buy |
31,528
+960
| +3% | +$159K | 0.37% | 57 |
|
|
2024
Q1 | $5.57M | Buy |
30,568
+1,413
| +5% | +$244K | 0.39% | 56 |
|
|
2023
Q4 | $4.52M | Buy |
29,155
+3,681
| +14% | +$537K | 0.34% | 60 |
|
|
2023
Q3 | $3.8M | Buy |
25,474
+617
| +2% | +$90.6K | 0.31% | 64 |
|
|
2023
Q2 | $3.35M | Sell |
24,857
-481
| -2% | -$70.5K | 0.26% | 72 |
|
|
2023
Q1 | $4.04M | Sell |
25,338
-398
| -2% | -$60.8K | 0.32% | 61 |
|
|
2022
Q4 | $4.16M | Buy |
25,736
+890
| +4% | +$136K | 0.33% | 65 |
|
|
2022
Q3 | $3.33M | Buy |
24,846
+535
| +2% | +$76.8K | 0.28% | 80 |
|
|
2022
Q2 | $3.72M | Buy |
24,311
+1,348
| +6% | +$206K | 0.28% | 75 |
|
|
2022
Q1 | $3.72M | Buy |
22,963
+4,692
| +26% | +$682K | 0.24% | 92 |
|
|
2021
Q4 | $2.47M | Sell |
18,271
-1,272
| -7% | -$150K | 0.15% | 124 |
|
|
2021
Q3 | $2.11M | Sell |
19,543
-2,131
| -10% | -$243K | 0.13% | 129 |
|
|
2021
Q2 | $2.44M | Sell |
21,674
-4,510
| -17% | -$508K | 0.16% | 122 |
|
|
2021
Q1 | $2.83M | Sell |
26,184
-2,770
| -10% | -$296K | 0.21% | 111 |
|
|
2020
Q4 | $3.1M | Buy |
28,954
+503
| +2% | +$48.3K | 0.23% | 108 |
|
|
2020
Q3 | $2.49M | Hold |
28,451
| – | – | 0.21% | 110 |
|
|
2020
Q2 | $2.79M | Buy |
28,451
+149
| +0.5% | +$13.1K | 0.26% | 100 |
|
|
2020
Q1 | $2.16M | Sell |
28,302
-2,579
| -8% | -$220K | 0.24% | 106 |
|
|
2019
Q4 | $2.73M | Sell |
30,881
-3,898
| -11% | -$324K | 0.27% | 94 |
|
|
2019
Q3 | $2.63M | Buy |
34,779
+14,265
| +70% | +$978K | 0.28% | 91 |
|
|
2019
Q2 | $1.49M | Sell |
20,514
-4,027
| -16% | -$317K | 0.16% | 124 |
|
|
2019
Q1 | $1.98M | Buy |
24,541
+230
| +0.9% | +$18.8K | 0.23% | 101 |
|
|
2018
Q4 | $2.24M | Sell |
24,311
-194
| -0.8% | -$17.1K | 0.3% | 85 |
|
|
2018
Q3 | $2.32M | Buy |
24,505
+8,613
| +54% | +$817K | 0.27% | 101 |
|
|
2018
Q2 | $1.47M | Buy |
+15,892
| New | +$1.55M | 0.19% | 120 |
|
Other funds holding ABBV
VCM
VPM
Equitable Trust's ABBV Position: Q1 2026 in Review
Equitable Trust reduced its AbbVie (ABBV) stake by 3.3% in Q1 2026, selling an estimated $267K and leaving 35,133 shares worth $7.64M. The position accounts for 0.35% of the portfolio, ranked #59.
Equitable Trust first reported a position in ABBV in Q2 2018 and has held it in 32 quarters since. The position peaked at $8.33M in Q3 2025. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Equitable Trust held 35,133 shares of AbbVie worth $7.64M as of Q1 2026.
- Equitable Trust sold 1,202 AbbVie shares in Q1 2026, an estimated $267K.
- AbbVie made up 0.35% of Equitable Trust's portfolio in Q1 2026, its #59 holding.
- Equitable Trust first reported a position in AbbVie in Q2 2018 and has held it in 32 quarters since.
- Equitable Trust's AbbVie position peaked at $8.33M in Q3 2025.
- 4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Equitable Trust's 13F filing for Q1 2026, filed 30 Apr 2026.